Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
Citigroup Initiates Coverage On Pliant Therapeutics with Buy Rating, Announces Price Target of $36
Citigroup analyst David Lebowitz initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Buy rating and announces Price Target of $36.
Cantor Fitzgerald Maintains Overweight on Pliant Therapeutics, Raises Price Target to $40
Cantor Fitzgerald analyst Pete Stravropoulos maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and raises the price target from $36 to $40.
The Daily Biotech Pulse: AstraZeneca’s COVID-19 Vaccine As Effective As mRNA Shots, Humanigen’s Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth’s Alzheimer’s Program
Here's a roundup of top developments in the biotech space over the last 24 hours:
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers
Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers
Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June.
Nasdaq Tumbles 2%; Pliant Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading following the release of jobs report on Friday.